Journal of Neuro-Oncology

, Volume 10, Issue 1, pp 47–55

Pharmacokinetics of 11C-labelled BCNU and SarCNU in gliomas studied by PET

  • S. Mitsuki
  • M. Diksic
  • T. Conway
  • Y. L. Yamamoto
  • J. -G. Villemure
  • W. Feindel
Clinical Study

DOI: 10.1007/BF00151246

Cite this article as:
Mitsuki, S., Diksic, M., Conway, T. et al. J Neuro-Oncol (1991) 10: 47. doi:10.1007/BF00151246

Summary

This paper describes the study of the pharmacodynamics of two 11C-labelled nitrosoureas, 1,3-bis-(2-chloroethyl) nitrosourea (BNCU) and sarcosinamide chloroethylnitrosourea (SarCNU), both labelled in the carbonyl position. Distribution of the radioactivity as measured by positron emission tomography was compared to the distribution of radioactivity observed after injection of 68Ga-EDTA, this being used as an indicator of the blood-brain barrier integrity around the brain tumor. Data suggest that the new nitrosourea, SarCNU, most likely enters brain tissue by different mechanism(s) than BCNU, which enters by diffusion. Data also indicate that use of SarCNU may result in a better tumor to brain ratio than BCNU.

Key words

nitrosoureasgliomaBCNUSarCNUPETchemotherapybrain tumorBBB

Copyright information

© Kluwer Academic Publishers 1991

Authors and Affiliations

  • S. Mitsuki
    • 1
    • 2
  • M. Diksic
    • 1
    • 2
  • T. Conway
    • 1
    • 2
  • Y. L. Yamamoto
    • 1
    • 2
  • J. -G. Villemure
    • 1
    • 2
  • W. Feindel
    • 1
    • 2
  1. 1.McConnell Brain Imaging Centre, Montreal Neurological InstituteMcGill UniversityMontrealCanada
  2. 2.Hospital and the Department of Neurology and NeurosurgeryMcGill UniversityMontrealCanada
  3. 3.Medical Cyclotron UnitMontreal Neurological Institute and HospitalMontrealCanada